Signal: Novo Nordisk’s Wegovy enters new borders

Novo Nordisk’s obesity drug, Wegovy, has launched in the UK, leading the company’s shares to surge to a record high. However, supply of the drug will be “controlled and limited” due to increasing demand. The drug will be allocated to individuals meeting specific health criteria. The launch follows research showing Wegovy can reduce heart-failure-related symptoms in obese individuals.